Red Tree Venture Capital, a San Francisco, CA-based early stage-biased life science venture capital firm, added Jeremy Caldwell as a partner.
Based in San Diego, Dr. Caldwell’s addition marks the firm’s increased emphasis on targeting company creation and investment opportunities from the San Diego area. This market has long served as a hotbed of academic entrepreneurs, life sciences talent, and pharma leadership, providing a fertile environment for Red Tree to expand its current operations beyond the Bay Area.
Jeremy Caldwell, Ph.D., is a biopharmaceutical executive and research and development leader, whose accomplishments span from the creation of innovative drug development companies to driving the discovery, development and translation of novel therapies, has joined the firm as a partner. Dr. Caldwell brings Red Tree a range of deep industry expertise built throughout a career involving roles as a member of both industry and the venture community. In alignment with the firm’s West Coast focus, he has forged deep ties within the San Diego and San Francisco Bay Area biotechnology communities.
In his previous roles with Inception Therapeutics and Versant Ventures, Dr. Caldwell co-led in the formation of Chinook Therapeutics, which was acquired by Novartis in a deal valued at up to $3.5 Billion, and co-led the investment and formation of Lycia Therapeutics, and Belharra Therapeutics, among others, acting as founding CEO and board director for each company. Prior to Inception/Versant, Dr. Caldwell was an entrepreneur-in-residence at Third Rock Ventures, where he participated in the genesis and formation of Revolution Medicines (RVMD), Pliant Therapeutics (PLRX), Decibel Therapeutics (DBTX), and Nurix Therapeutics (NRIX).
Commenting on the news, Dr. Caldwell said: “In my experience, San Diego is home to a wealth of scientists and entrepreneurs, along with broad-reaching skilled life sciences talent and access to Big Pharma. This confluence of key factors highlights San Diego as a major player in the biopharma space and gives me great excitement for the position that Red Tree can establish within the San Diego ecosystem.”
Founded in 2020 by Heath Lukatch, Ph.D., and Jennifer Cochran, Ph.D., later joined by managing director Jon Edwards, Ph.D., Red Tree Venture Capital is a West Coast-centric, early stage-biased life science venture capital firm. The firm has raised an inaugural $272M fund, Red Tree Venture Capital Fund I, to create and invest in companies developing therapeutics and technologies in the areas of oncology, neurology and immunology.
The investment approach employed by the team is built upon the following four pillars:
- West Coast-Centric: Focused on investing in life science innovation emerging from premier academic and research institutions on the West Coast of the United States.
- Early Stage-Biased: Supporting breakthrough science from its very first steps, seeking to create companies or providing funding to established groups at their seed, preclinical or early clinical stages.
- Best-in-Class and/or First-in-Class Therapeutics: Dedicated to advancing cutting-edge science with the potential to deliver best-in-class and/or first-in-class therapeutics that transform patient lives.
- Oncology, Neurology & Immunology: Therapeutic focus in the areas of cancer, neurological disease and immunological disease.